Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Our work is reader-supported. Sign up to our free or paid plans here.
A recap of our discussion at SXSW 2025, which featured Graham Pechenik, Shayla Love, Jane Hu, and Josh Hardman and explored the changing face of psychedelic companies, the role of journalism in the field, predictions for the next five years, and much more.
Psychedelic Alphaās Josh Hardman sits down with Sunstone Therapies co-founders Manish Agrawal and Kim Roddy to tease out their learnings from delivering hundreds of psychedelic therapy sessions at their purpose-designed facility.
āEuropeās Most Feared Investorā Teams Up with Musk Associate to Fund Lykos Therapeutics ā¢ Risk-Off or Reality Check? Psychedelic Stocks Slump After RFK Jr. Surge ā¢ Beckley Wraps Enrolment for Phase 2b Study of 5-MeO-DMT in Treatment-Resistant Depression ā¢ PATH Caucus RFI Submissions Roll In ā¢ Australian VA Mulls Funding Psychedelic Therapy ā¢ First Sponsored LSD Trial in the UK ā¢ and more…
Now that the rules for Coloradoās regulated psychedelics program are set and license applications are open, Healing Advocacy Fundās Colorado Director Tasia Poinsatte provides a brief, straightforward overview of the program and its key regulations.
Josh Hardman sits down with Congressmen Lou Correa and Jack Bergman to discuss their psychedelics-focused Congressional Caucus. They talk about the initiativeās progress to date, what it looks like to muster support for psychedelics in Washington in light of FDAās MDMA rejection, and what the new U.S. administration means for their work and the field more broadly.
āIāve Never Been More Hopefulā ā Psychedelic Philanthropists Weigh In on New Administration ā¢ Psilocybin and Ibogaine Bills Spark Debate Among Washington State Lawmakers, Medical Experts, and Psychedelic Community ā¢ Johns Hopkins Opens Clinic to Treat Individuals Experiencing Post-Psychedelic Difficulties ā¢ Compass Shares Q4ā24 and FYā24 Results, PTSD Development Back on the Agenda ā¢ GH Research Shares FYā24 Results, Hopes to Submit FDA Hold Response By Mid-Year ā¢ and more…
Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.
TheĀ Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.
It’s exclusively available to our PĪ±+ subscribers, with new content added regularly.
PĪ±+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.
PĪ±+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.
Archived versions of our Psychedelic News Feed.
This is an archived version of our Psychedelic News Feed, from September 2 to December 29, 2024.
This is an archived version of our Psychedelic News Feed, from March 4, 2024 – September 1, 2024.
A special version of our Psychedelic News Feed to mark April 1st, 2024.
This is an archived version of our Psychedelic News Feed, from February 5 2024 – March 3 2024ā.
This is an archived version of our Psychedelic News Feed, from January 8 2024 – February 4 2024ā.
This is an archived version of our Psychedelic News Feed, from December 11 2023 – January 7 2024ā.
Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond
Insights and interviews delivered to your inbox. No spam, just valuable information.
